Qiagen introduces bioinformatics solution for hereditary disease

Qiagen has announced the launch of a new bioinformatics solution for hereditary diseases, designed to enhance and accelerate analysis and interpretation of next-generation sequencing data.

The new solution for research labs is designed to accelerate solve rates in diagnostic odyssey cases, while enabling researchers to directly focus on the right causal candidates, thus freeing up time and resources.

It encompasses Qiagen's Biomedical Genomics Workbench, Biomedical Genomics Server Solution, Ingenuity Variant Analysis, and HGMD Human Gene Mutation Database.

The company estimates that laboratories using this new hereditary disease solution can achieve a case solve rate as high as 99 percent, while significantly reducing the rate of irrelevant variants for follow-up by between 94 and 100 percent.

Dr Laura Furmanski, head of Qiagen's bioinformatics business area, said: "Qiagen continues to expand our solutions to enable the incredible advances that clinical research labs are making every day, particularly in next-generation sequencing for hereditary diseases."

This comes after the firm launched RespiFast RG Panel for the detection of respiratory tract infections in Europe last month.